We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Albireo Pharma on Tuesday said the FDA cleared Bylvay (odevixibat) to treat moderate-to-severe itching in patients aged three months and older with progressive familial intrahepatic cholestasis (PFIC), making it the first drug approved for all subtypes of